Breckenridge secures marketing agreement with Gland Pharma for 7 injectables

By Melissa Fassbender

- Last updated on GMT

The injectable products cover a range of indications. (Image: iStock/Mckyartstudio)
The injectable products cover a range of indications. (Image: iStock/Mckyartstudio)

Related tags Pharmaceutical drug Pharmacology

Breckenridge Pharmaceutical has entered into a multi-product marketing agreement with development and manufacturing partner Gland Pharma Limited for seven injectable products.

Per the agreement, Breckenridge will market and distribute six approved ANDAs and one tentatively-approved ANDA under its label in the United States.

Breckenridge announced its entry into the injectable market​ in November with the launch of Methylergonovine Maleate Injection. The company commented at the time that the launch was “the first of several planned injectable products​” expected in the near future.

The company also announced a license to market Armodafinil​ tablets – a generic version of Nuvigil® by Cephalon – in partnership with Natco Pharma Limited.

Related news

Show more

Related product

Follow us

Products

View more

Webinars